Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome
Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ZEL | Ann: Z Energy Limited ("ZEL") - Trading Suspension and Delisting | 27/08/24 | 0 | 55 | |||
|
|||||||
ZEL | Ann: Z Energy Half Year Report 30 June 2024 | 26/08/24 | 0 | 72 | |||
|
|||||||
ZEL | Ann: Z Energy Limited ("ZEL060") - Maturity | 15/08/24 | 0 | 83 | |||
|
|||||||
ZEL | Ann: Director appointed to Z Energy Limited | 28/05/24 | 0 | 133 | |||
|
|||||||
ZEL | Ann: Board Chair appointed to Z Energy Limited | 19/03/24 | 0 | 118 | |||
|
|||||||
ZEL | Ann: Z Energy Annual Report to 31 December 2023 | 29/02/24 | 0 | 124 | |||
|
|||||||
ZEL | Ann: Director appointed to Z Energy Limited | 20/12/23 | 0 | 156 | |||
|
|||||||
ZEL | Ann: Z Energy Limited ("ZEL050") - Maturity | 12/10/23 | 0 | 153 | |||
|
See All Discussions